Travel COVID Test centre has been opened at Jerez Airport to provide passengers with their required COVID-19 tests to travel: antigen tests, PCR tests and rapid antibody tests.
The latest innovation
and company news
Arquimea and Circadian Therapeutics sign a collaboration agreement for the development of a molecule (AP-2) for the treatment of diseases affecting the nervous system
The Spanish technology company ARQUIMEA, Ankar Pharma and Circadian Therapeutics have signed an agreement for the co-development of molecules as an innovative treatment for nervous system diseases such as ALS, Parkinson’s or Alzheimer’s disease.
ARQUIMEA, the healthcare partner tasked with establishing the different COVID-19 protocols in Mutua Madrid Open for the biggest international tennis event.
EpiDisease receives an investment of 535,000€ for the development of diagnostic tests with epigenetic markers
EpiDisease receives an investment of 535,000€ for the development of diagnostic tests with epigenetic markers. Arquimea and the Fundación Botín invest in diagnostic tests based on epigenetics which will accelerate the market launch of this technology and undertake trials in Spanish hospitals.
Starting this week, travellers from Madrid-Barajas, Malaga, and Seville airports will have a COVID 19 test service in their departure terminals
Starting this week, travellers from Madrid-Barajas, Malaga, and Seville airports will have a COVID 19 test service in their departure terminals. This service will permit taking PCR Tests and Rapid Antigen Tests to travellers and crews, who need to prove they underwent these tests during their journey.
Health, a priority at the Andalucía Costa del Sol Open in Spain. ARQUIMEA, an essential healthcare partner in the final appointment of the Race to Costa del Sol
ARQUIMEA protects all those who participate or work in the Andaluía Costa del Sol Open, establishing protocols and getting PCR for all of them.